Junwen Wang MD, Pijuan Xiao MM, Yuyang Ye MM, Xuefeng Chen MM, Xinru Hu MM, Yuanrui Yang MD, Yong Peng MD
Although hypertension is highly prevalent among the elderly and significantly contributes to cardiovascular disease risk, studies focusing on male elderly individuals over 85 years old are relatively scarce. This study aimed to investigate ambulatory blood pressure monitoring (ABPM) characteristics in male hypertensive patients aged over 85 years. These included demographic characteristics, antihypertensive drug use, 24-h ABPM values, diabetes, coronary heart disease, sleep disorders, smoking history, and drinking history, and the differences in ABPM between the age groups over and under 85 years old were analyzed. A total of 585 elderly hypertensive patients were included. The mean systolic blood pressure in individuals aged over 85 years was significantly greater throughout the day (131.57 ± 12.52 mmHg vs. 123.75 ± 2.74 mmHg, p < .001). In the 85 years older age group, the nighttime variability coefficient of SBP was lower at 7.84 ± 2.9 than the under 85 years age group 8.92 ± 3.13 (p < .001). The 85 years older age group age group presented a significantly greater whole-day systolic blood pressure standard deviation of ABPM (13.2 ± 3.19 vs. 12.47 ± 3.05, p = .005) compared with those under the age of 85 years. In the 85 years older age group, the proportion of individuals with the reverse dipper pattern was higher (48.15% vs. 38.31%, p = .017) than under 85 years age group. This study revealed that elderly male hypertensive patients aged over 85 years presented elevated average blood pressure levels. The research investigated ABPM characteristics. Older hypertensive individuals are more likely to have a reverse-dipper blood pressure pattern.
{"title":"Characteristics of 24-h ambulatory blood pressure monitoring in elderly hypertensive males: An observational study of 85 year older patients","authors":"Junwen Wang MD, Pijuan Xiao MM, Yuyang Ye MM, Xuefeng Chen MM, Xinru Hu MM, Yuanrui Yang MD, Yong Peng MD","doi":"10.1111/jch.14897","DOIUrl":"10.1111/jch.14897","url":null,"abstract":"<p>Although hypertension is highly prevalent among the elderly and significantly contributes to cardiovascular disease risk, studies focusing on male elderly individuals over 85 years old are relatively scarce. This study aimed to investigate ambulatory blood pressure monitoring (ABPM) characteristics in male hypertensive patients aged over 85 years. These included demographic characteristics, antihypertensive drug use, 24-h ABPM values, diabetes, coronary heart disease, sleep disorders, smoking history, and drinking history, and the differences in ABPM between the age groups over and under 85 years old were analyzed. A total of 585 elderly hypertensive patients were included. The mean systolic blood pressure in individuals aged over 85 years was significantly greater throughout the day (131.57 ± 12.52 mmHg vs. 123.75 ± 2.74 mmHg, <i>p</i> < .001). In the 85 years older age group, the nighttime variability coefficient of SBP was lower at 7.84 ± 2.9 than the under 85 years age group 8.92 ± 3.13 (<i>p</i> < .001). The 85 years older age group age group presented a significantly greater whole-day systolic blood pressure standard deviation of ABPM (13.2 ± 3.19 vs. 12.47 ± 3.05, <i>p</i> = .005) compared with those under the age of 85 years. In the 85 years older age group, the proportion of individuals with the reverse dipper pattern was higher (48.15% vs. 38.31%, <i>p</i> = .017) than under 85 years age group. This study revealed that elderly male hypertensive patients aged over 85 years presented elevated average blood pressure levels. The research investigated ABPM characteristics. Older hypertensive individuals are more likely to have a reverse-dipper blood pressure pattern.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 11","pages":"1237-1245"},"PeriodicalIF":2.7,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chaoyi Chen MD, Aiting Liu MD, Zhengzhipeng Zhang MD, Jie Chen MD, PhD, Hui Huang MD, PhD
Various digital therapeutic products have been validated and approved since 2017. They have demonstrated efficacy and safety as a new therapeutic modality in various disorders or conditions. Hypertension is a common but serious condition that can be prevented or controlled with lifestyle changes and medicines. Although a digital therapeutic in hypertension is validated and approved in Japan, whether digital therapeutics (DTx) can significantly improve sustainable lifestyle changes is still a controversial topic. Most studies did not discuss the long-term gain challenges. In this review, the authors discuss the definition of DTx, and analyze the motivation, engagement and adherence challenges of DTx in hypertension. Some ongoing artificial intelligence (AI)-enabled or cognitive behavioral therapy (CBT)-based digital interventions and behavioral strategies for implementing sustainable lifestyle changes are identified and analyzed. With AI-enabled interventions and behavioral strategies, DTx might be one of the effective approaches to make sustainable lifestyle changes.
{"title":"Digital therapeutics in hypertension: How to make sustainable lifestyle changes","authors":"Chaoyi Chen MD, Aiting Liu MD, Zhengzhipeng Zhang MD, Jie Chen MD, PhD, Hui Huang MD, PhD","doi":"10.1111/jch.14894","DOIUrl":"10.1111/jch.14894","url":null,"abstract":"<p>Various digital therapeutic products have been validated and approved since 2017. They have demonstrated efficacy and safety as a new therapeutic modality in various disorders or conditions. Hypertension is a common but serious condition that can be prevented or controlled with lifestyle changes and medicines. Although a digital therapeutic in hypertension is validated and approved in Japan, whether digital therapeutics (DTx) can significantly improve sustainable lifestyle changes is still a controversial topic. Most studies did not discuss the long-term gain challenges. In this review, the authors discuss the definition of DTx, and analyze the motivation, engagement and adherence challenges of DTx in hypertension. Some ongoing artificial intelligence (AI)-enabled or cognitive behavioral therapy (CBT)-based digital interventions and behavioral strategies for implementing sustainable lifestyle changes are identified and analyzed. With AI-enabled interventions and behavioral strategies, DTx might be one of the effective approaches to make sustainable lifestyle changes.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 10","pages":"1125-1132"},"PeriodicalIF":2.7,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meiqi Chen , Juan Liu , Menglin Fan , Bin Li MD, Yong Ren MD, Shaoyong Xu MD
This study was conducted to investigate the association between alcohol consumption in adolescence and the risk of hypertension or prehypertension development in early adulthood. This cohort study included adolescent participants aged 12–18 years from the 2000–2011 China Health and Nutrition Survey. Cox proportional risk regression models were used to analyze the associations of the frequency of alcohol consumption, alcohol intake, and type of alcohol with the risk of developing hypertension or prehypertension. Restricted cubic spline analysis was used to assess the dose–response relationships for alcohol intake and their hazard ratios (HRs). A total of 1556 participants were included in the final analysis. Among the overall population, 448 (30.81%) and 35 (34.31%) participants developed hypertension or prehypertension, respectively. Compared with no alcohol consumption, alcohol consumption ≥ 2 times/week and consumption of ≥2 types of alcohol were associated with an increased risk of hypertension and prehypertension, with HRs of 1.97 (95% confidence interval [CI] 1.17–3.34; p = 0.011) and 1.77 (95% CI 1.01–3.09; p = 0.046), respectively. Alcohol intake of > 96 mL/week was associated with an increased risk of hypertension and prehypertension, with HRs of 2.09 (95% CI 1.12–3.90; p = 0.020) and 2.07 (95% CI 1.11–3.84; p = 0.021), respectively. The restricted cubic spline analysis showed that the risk of developing high blood pressure or prehypertension tends to increase with increasing alcohol consumption. Heavy alcohol consumption in adolescence increased the risk of developing hypertension and prehypertension in early adulthood.
本研究旨在探讨青少年时期饮酒与成年早期高血压或高血压前期发展风险之间的关系。这项队列研究纳入了2000-2011年中国健康与营养调查中12-18岁的青少年参与者。研究采用Cox比例风险回归模型分析饮酒频率、酒精摄入量和酒精种类与高血压或高血压前期发病风险的关系。限制立方样条分析用于评估酒精摄入量的剂量-反应关系及其危险比(HRs)。最终分析共纳入了 1556 名参与者。在总体人群中,分别有 448 人(30.81%)和 35 人(34.31%)罹患高血压或高血压前期。与不饮酒相比,饮酒≥2次/周和饮酒≥2种与高血压和高血压前期风险增加有关,HR值分别为1.97(95% 置信区间[CI] 1.17-3.34;P = 0.011)和1.77(95% CI 1.01-3.09;P = 0.046)。酒精摄入量大于 96 毫升/周与高血压和高血压前期风险增加有关,HR 分别为 2.09 (95% CI 1.12-3.90; p = 0.020) 和 2.07 (95% CI 1.11-3.84; p = 0.021)。限制性三次样条分析表明,随着饮酒量的增加,患高血压或高血压前期的风险呈上升趋势。青少年时期大量饮酒会增加成年早期罹患高血压和高血压前期的风险。
{"title":"Association of alcohol consumption with hypertension or prehypertension in Chinese adolescent: A cohort study of the China Health and Nutrition Survey","authors":"Meiqi Chen , Juan Liu , Menglin Fan , Bin Li MD, Yong Ren MD, Shaoyong Xu MD","doi":"10.1111/jch.14895","DOIUrl":"10.1111/jch.14895","url":null,"abstract":"<p>This study was conducted to investigate the association between alcohol consumption in adolescence and the risk of hypertension or prehypertension development in early adulthood. This cohort study included adolescent participants aged 12–18 years from the 2000–2011 China Health and Nutrition Survey. Cox proportional risk regression models were used to analyze the associations of the frequency of alcohol consumption, alcohol intake, and type of alcohol with the risk of developing hypertension or prehypertension. Restricted cubic spline analysis was used to assess the dose–response relationships for alcohol intake and their hazard ratios (HRs). A total of 1556 participants were included in the final analysis. Among the overall population, 448 (30.81%) and 35 (34.31%) participants developed hypertension or prehypertension, respectively. Compared with no alcohol consumption, alcohol consumption ≥ 2 times/week and consumption of ≥2 types of alcohol were associated with an increased risk of hypertension and prehypertension, with HRs of 1.97 (95% confidence interval [CI] 1.17–3.34; <i>p</i> = 0.011) and 1.77 (95% CI 1.01–3.09; <i>p</i> = 0.046), respectively. Alcohol intake of > 96 mL/week was associated with an increased risk of hypertension and prehypertension, with HRs of 2.09 (95% CI 1.12–3.90; <i>p</i> = 0.020) and 2.07 (95% CI 1.11–3.84; <i>p</i> = 0.021), respectively. The restricted cubic spline analysis showed that the risk of developing high blood pressure or prehypertension tends to increase with increasing alcohol consumption. Heavy alcohol consumption in adolescence increased the risk of developing hypertension and prehypertension in early adulthood.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 11","pages":"1228-1236"},"PeriodicalIF":2.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lei Xu BS, Kai Wang PhD, Tao Yan MD, Lehui Li MD, Yu Miao MD, Zixuan Tian MD, Ru Zhang MD, Ya Wang BS, Chunfa Zhang BS, Jinli Yan BS, Ning Cao PhD, Nan Zhang PhD, Xingguang Zhang PhD
The study aimed to assess the impact of changes in blood pressure on cardiovascular events in the Chinese population. It enrolled 33 179 Chinese participants aged ≥35 years (57.1% women) without CVD at baseline. BP status was defined according to the 2017 ACC/AHA hypertension guidelines. The type of BP change was defined as change in BP status from baseline to the end of follow-up, included stable BP <130/80, <130/80 to ≥130/80, ≥130/80 to <130/80 mm Hg, persistent BP ≥130/80 mm Hg. The hazard ratio (HR) of incident CVD by change in BP category was estimated using Cox proportional hazards and Fine–Gray models. During median follow-up of 3.17 years, 2023 CVD events occurred. Compared with BP <120/80, 120–129/<80 mm Hg at baseline (HR = 1.66, 95% CI: 1.09–2.53), 130–139/80–89 mm Hg (HR = 1.35, 95% CI: 0.94–1.95), and ≥140/90 mm Hg (HR = 2.46, 95% CI: 1.78–3.40) were risk factors for CVD. Compared with the group with stable BP <130/80 mm Hg, the risk of CVD was 1.88 (95% CI: 1.40–2.53) in the group with persistent BP ≥130/80 mm Hg and 1.40 (95% CI: 1.01–1.94) in the group of BP decreased to <130/80 mm Hg. These results showed that BP 120–129/<80, 130–139/80–89, and ≥140/90 mm Hg were associated with a high risk of CVD. Over time, persistent BP ≥130/80 mm Hg increased the risk of CVD, but a return to <130/80 mm Hg from hypertension decreased the risk of CVD.
{"title":"Risk analysis of blood pressure changes on cardiovascular disease in Chinese population","authors":"Lei Xu BS, Kai Wang PhD, Tao Yan MD, Lehui Li MD, Yu Miao MD, Zixuan Tian MD, Ru Zhang MD, Ya Wang BS, Chunfa Zhang BS, Jinli Yan BS, Ning Cao PhD, Nan Zhang PhD, Xingguang Zhang PhD","doi":"10.1111/jch.14888","DOIUrl":"10.1111/jch.14888","url":null,"abstract":"<p>The study aimed to assess the impact of changes in blood pressure on cardiovascular events in the Chinese population. It enrolled 33 179 Chinese participants aged ≥35 years (57.1% women) without CVD at baseline. BP status was defined according to the 2017 ACC/AHA hypertension guidelines. The type of BP change was defined as change in BP status from baseline to the end of follow-up, included stable BP <130/80, <130/80 to ≥130/80, ≥130/80 to <130/80 mm Hg, persistent BP ≥130/80 mm Hg. The hazard ratio (HR) of incident CVD by change in BP category was estimated using Cox proportional hazards and Fine–Gray models. During median follow-up of 3.17 years, 2023 CVD events occurred. Compared with BP <120/80, 120–129/<80 mm Hg at baseline (HR = 1.66, 95% CI: 1.09–2.53), 130–139/80–89 mm Hg (HR = 1.35, 95% CI: 0.94–1.95), and ≥140/90 mm Hg (HR = 2.46, 95% CI: 1.78–3.40) were risk factors for CVD. Compared with the group with stable BP <130/80 mm Hg, the risk of CVD was 1.88 (95% CI: 1.40–2.53) in the group with persistent BP ≥130/80 mm Hg and 1.40 (95% CI: 1.01–1.94) in the group of BP decreased to <130/80 mm Hg. These results showed that BP 120–129/<80, 130–139/80–89, and ≥140/90 mm Hg were associated with a high risk of CVD. Over time, persistent BP ≥130/80 mm Hg increased the risk of CVD, but a return to <130/80 mm Hg from hypertension decreased the risk of CVD.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 11","pages":"1219-1227"},"PeriodicalIF":2.7,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura Würzburger MD, Jan Gerrit van der Stouwe MD, Céline Ghidoni MD, Patrick Wiech MD, Georg Moser MD, Gloria Petrasch MD, Victor Schweiger MD, Philipp Bohm MD, Valentina A. Rossi MD, Christian Templin MD, Stefano Caselli MD, Christian M. Schmied MD, David Niederseer MD, PhD
A hypertensive response to exercise is a precursor leading to hypertension, which is a major risk factor for the development of heart failure and diastolic dysfunction. Herein, we aimed to assess blood pressure (BP) in patients with a hypertensive response to exercise and different degrees of diastolic dysfunction. Between January 2009 and December 2014, 373 patients with a hypertensive response to exercise (HRE) and echocardiographic data assessing diastolic function were enrolled at the University Hospital of Zurich. ANCOVA was used to assess the changes in BP response during exercise testing in individuals with different degrees of diastolic dysfunction. Normalization of systolic BP was blunted in patients with grade II and III diastolic dysfunction after 3 min of recovery in univariable [β (95%) - 9.2 (-13.8 to - 4.8) p < .001, -16.0 (-23.0 to 9.0) p < .001, respectively] and adjusted models. In fully adjusted models, when taking maximal effort into account, there were no differences with regard to systolic BP during exercise. Patients without diastolic dysfunction achieved higher heart rates (HRs) [both in absolute terms (p < .001) and as a percentage of the calculated maximum (p = .003)] and greater wattage (p < .001) at maximum exertion. The findings of this cross-sectional study suggest that exercise capacity is compromised in patients with diastolic dysfunction. A hypertensive response to exercise and the finding of a blunted BP recovery may help identify patients at risk of developing heart failure.
{"title":"Blood pressure behavior during exercise in patients with diastolic dysfunction and a hypertensive response to exercise","authors":"Laura Würzburger MD, Jan Gerrit van der Stouwe MD, Céline Ghidoni MD, Patrick Wiech MD, Georg Moser MD, Gloria Petrasch MD, Victor Schweiger MD, Philipp Bohm MD, Valentina A. Rossi MD, Christian Templin MD, Stefano Caselli MD, Christian M. Schmied MD, David Niederseer MD, PhD","doi":"10.1111/jch.14884","DOIUrl":"10.1111/jch.14884","url":null,"abstract":"<p>A hypertensive response to exercise is a precursor leading to hypertension, which is a major risk factor for the development of heart failure and diastolic dysfunction. Herein, we aimed to assess blood pressure (BP) in patients with a hypertensive response to exercise and different degrees of diastolic dysfunction. Between January 2009 and December 2014, 373 patients with a hypertensive response to exercise (HRE) and echocardiographic data assessing diastolic function were enrolled at the University Hospital of Zurich. ANCOVA was used to assess the changes in BP response during exercise testing in individuals with different degrees of diastolic dysfunction. Normalization of systolic BP was blunted in patients with grade II and III diastolic dysfunction after 3 min of recovery in univariable [β (95%) - 9.2 (-13.8 to - 4.8) <i>p</i> < .001, -16.0 (-23.0 to 9.0) <i>p</i> < .001, respectively] and adjusted models. In fully adjusted models, when taking maximal effort into account, there were no differences with regard to systolic BP during exercise. Patients without diastolic dysfunction achieved higher heart rates (HRs) [both in absolute terms (<i>p</i> < .001) and as a percentage of the calculated maximum (<i>p</i> = .003)] and greater wattage (<i>p</i> < .001) at maximum exertion. The findings of this cross-sectional study suggest that exercise capacity is compromised in patients with diastolic dysfunction. A hypertensive response to exercise and the finding of a blunted BP recovery may help identify patients at risk of developing heart failure.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 11","pages":"1209-1218"},"PeriodicalIF":2.7,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael E. Ernst PharmD, Kevin Phan MBiostat, Mark R. Nelson MBBS, PhD, Robyn L. Woods PhD, Michelle A. Fravel PharmD, Lawrence Beilin MB, MD, Suzanne G. Orchard PhD, Zhen Zhou PhD, Kevan R. Polkinghorne MBChB, PhD, Jonathan C. Broder MStat&OpRes, Karen L. Margolis MD, MPH, Christopher M. Reid PhD, Nigel Stocks MBBS, MD, Enayet Chowdhury MBBS, MP, PhD, Rory Wolfe PhD
High-quality randomized trial evidence is lacking on whether low-dose aspirin exerts significant effects on blood pressure (BP) in older adults. The authors assessed longitudinal BP changes in participants enrolled in ASPirin in Reducing Events in the Elderly (ASPREE), a randomized, placebo-controlled trial of 100 mg daily aspirin in 19 114 community-dwelling Australian and U.S. adults without cardiovascular disease (CVD), dementia, or independence-limiting physical disability. Participants’ BP was recorded at baseline and annual study visits, and managed by their usual care provider. BP trajectories for aspirin versus placebo during 4.7 years of follow-up were examined for systolic and diastolic BP separately, using linear mixed models to account for between and within-individual variability in BP. Analyses by subgroups were also explored with inclusion of interaction terms in the models. The difference in mean change in systolic BP between aspirin and placebo during study follow-up was −0.03 mm Hg (95% confidence interval [CI]: −0.13, 0.07; p = .541) (aspirin minus placebo), while the mean difference for change in diastolic BP was −0.05 mm Hg (95% CI: –0.11, 0.01; p = .094). These small, non-significant differences in BP change between the aspirin and placebo groups were consistent across baseline levels of BP and antihypertensive treatment status (treated/untreated). Likewise, subgroups of age, sex, chronic kidney disease, diabetes, and frailty revealed no interaction effect between the subgroup, aspirin treatment, and time. Interval-censored Cox proportional hazards regression showed no difference in rates of incident treated hypertension between aspirin and placebo-treated participants. The authors conclude that daily low-dose aspirin does not significantly affect BP in older adults when managed by usual care.
低剂量阿司匹林是否对老年人的血压(BP)有显著影响,目前还缺乏高质量的随机试验证据。作者评估了参加 ASPirin in Reducing Events in the Elderly (ASPREE) 研究的参与者的纵向血压变化情况,该研究是一项随机、安慰剂对照试验,对 19 114 名居住在社区的澳大利亚和美国成年人每天服用 100 毫克阿司匹林,这些人没有心血管疾病 (CVD)、痴呆或限制自理能力的肢体残疾。参与者的血压在基线和年度研究访问时均有记录,并由其日常护理人员进行管理。采用线性混合模型分别研究了阿司匹林与安慰剂在 4.7 年随访期间的收缩压和舒张压变化轨迹,以考虑血压在个体间和个体内的变化。在模型中加入交互项后,还对亚组进行了分析。在研究随访期间,阿司匹林和安慰剂的收缩压平均变化差异为-0.03毫米汞柱(95% 置信区间[CI]:-0.13,0.07;p = .541)(阿司匹林减去安慰剂),而舒张压变化的平均差异为-0.05毫米汞柱(95% 置信区间:-0.11,0.01;p = .094)。阿司匹林组与安慰剂组之间血压变化的这些微小而不显著的差异在血压基线水平和抗高血压治疗状态(治疗/未治疗)方面是一致的。同样,年龄、性别、慢性肾病、糖尿病和虚弱等亚组显示,亚组、阿司匹林治疗和时间之间没有交互作用。区间删失 Cox 比例危险度回归显示,阿司匹林治疗者和安慰剂治疗者的高血压发病率没有差异。作者的结论是,如果采用常规治疗,每日服用小剂量阿司匹林不会对老年人的血压产生明显影响。
{"title":"Daily low-dose aspirin and blood pressure in community-dwelling older adults","authors":"Michael E. Ernst PharmD, Kevin Phan MBiostat, Mark R. Nelson MBBS, PhD, Robyn L. Woods PhD, Michelle A. Fravel PharmD, Lawrence Beilin MB, MD, Suzanne G. Orchard PhD, Zhen Zhou PhD, Kevan R. Polkinghorne MBChB, PhD, Jonathan C. Broder MStat&OpRes, Karen L. Margolis MD, MPH, Christopher M. Reid PhD, Nigel Stocks MBBS, MD, Enayet Chowdhury MBBS, MP, PhD, Rory Wolfe PhD","doi":"10.1111/jch.14891","DOIUrl":"10.1111/jch.14891","url":null,"abstract":"<p>High-quality randomized trial evidence is lacking on whether low-dose aspirin exerts significant effects on blood pressure (BP) in older adults. The authors assessed longitudinal BP changes in participants enrolled in ASPirin in Reducing Events in the Elderly (ASPREE), a randomized, placebo-controlled trial of 100 mg daily aspirin in 19 114 community-dwelling Australian and U.S. adults without cardiovascular disease (CVD), dementia, or independence-limiting physical disability. Participants’ BP was recorded at baseline and annual study visits, and managed by their usual care provider. BP trajectories for aspirin versus placebo during 4.7 years of follow-up were examined for systolic and diastolic BP separately, using linear mixed models to account for between and within-individual variability in BP. Analyses by subgroups were also explored with inclusion of interaction terms in the models. The difference in mean change in systolic BP between aspirin and placebo during study follow-up was −0.03 mm Hg (95% confidence interval [CI]: −0.13, 0.07; <i>p</i> = .541) (aspirin minus placebo), while the mean difference for change in diastolic BP was −0.05 mm Hg (95% CI: –0.11, 0.01; <i>p</i> = .094). These small, non-significant differences in BP change between the aspirin and placebo groups were consistent across baseline levels of BP and antihypertensive treatment status (treated/untreated). Likewise, subgroups of age, sex, chronic kidney disease, diabetes, and frailty revealed no interaction effect between the subgroup, aspirin treatment, and time. Interval-censored Cox proportional hazards regression showed no difference in rates of incident treated hypertension between aspirin and placebo-treated participants. The authors conclude that daily low-dose aspirin does not significantly affect BP in older adults when managed by usual care.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 10","pages":"1188-1195"},"PeriodicalIF":2.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hypertensive disorders of pregnancy pose significant risks to both maternal and fetal health. Postpartum hypertension, a common complication, often leads to emergency room (ER) visits or hospital readmissions. Despite the prevalence of these complications, there is a paucity of studies that focus on blood pressure monitoring in postpartum patients with de novo hypertensive disorders of pregnancy. This review aimed to address the gap by evaluating available evidence to compare telehealth monitoring with in-person visits in preventing ER visits and hospital readmissions among postpartum patients with de novo hypertensive disorders of pregnancy. The study identified relevant studies by conducting a rigorous search strategy (Medline/OVID, the Cochrane Library, Scopus, and research registries such as the International Clinical Trials Registry Platform [ICTRP] and clinical trials) directed by the clinical information specialist. Two reviewers independently screened titles and abstracts, resolving discrepancies with the assistance of a third reviewer. Data extraction followed standardized protocols, and risk of bias assessments were conducted using appropriate tools. This rapid review synthesized evidence from 11 studies on telehealth for women with recent de novo hypertensive disorders of pregnancy. Findings highlighted that telemonitoring led to earlier blood pressure documentation and intervention, reduced disparities in blood pressure measurement, decreased hypertension-related readmissions, higher rates of postpartum antihypertensive treatment initiation, and increased patient satisfaction. Telehealth emerges as a promising tool for managing postpartum hypertension among women with recent de novo hypertensive disorders of pregnancy
{"title":"A rapid review of telehealth in women with recent de novo hypertensive disease of pregnancy","authors":"Toluwalase Awoyemi MD, PhD, Samira Teeri MD, Emmanuel Daniel MD, Isaac Ogunmola MD, Ujunwa Ebili MD, Eloho Olojakpoke MD, Rocio Barriga Guzman MD, Francis Ezekwueme MD, Denise Nunes MS, RN, MSLIS","doi":"10.1111/jch.14886","DOIUrl":"10.1111/jch.14886","url":null,"abstract":"<p>Hypertensive disorders of pregnancy pose significant risks to both maternal and fetal health. Postpartum hypertension, a common complication, often leads to emergency room (ER) visits or hospital readmissions. Despite the prevalence of these complications, there is a paucity of studies that focus on blood pressure monitoring in postpartum patients with de novo hypertensive disorders of pregnancy. This review aimed to address the gap by evaluating available evidence to compare telehealth monitoring with in-person visits in preventing ER visits and hospital readmissions among postpartum patients with de novo hypertensive disorders of pregnancy. The study identified relevant studies by conducting a rigorous search strategy (Medline/OVID, the Cochrane Library, Scopus, and research registries such as the International Clinical Trials Registry Platform [ICTRP] and clinical trials) directed by the clinical information specialist. Two reviewers independently screened titles and abstracts, resolving discrepancies with the assistance of a third reviewer. Data extraction followed standardized protocols, and risk of bias assessments were conducted using appropriate tools. This rapid review synthesized evidence from 11 studies on telehealth for women with recent de novo hypertensive disorders of pregnancy. Findings highlighted that telemonitoring led to earlier blood pressure documentation and intervention, reduced disparities in blood pressure measurement, decreased hypertension-related readmissions, higher rates of postpartum antihypertensive treatment initiation, and increased patient satisfaction. Telehealth emerges as a promising tool for managing postpartum hypertension among women with recent de novo hypertensive disorders of pregnancy</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 9","pages":"1015-1023"},"PeriodicalIF":2.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.14886","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juan Peng MM, Quxi Zhao MM, Wei Pang MM, Yanjuan Li MM, Xudong Dong PhD
Preeclampsia (PE) is a severe pregnancy complication characterized by significant alterations in coagulation function. This study aims to analyze the correlation between coagulation function, platelet parameters, and pregnancy outcomes in PE patients. Clinical data, along with blood and urine samples, were collected from 168 PE patients and 128 healthy pregnant women. General demographic and laboratory testing data were recorded, and maternal and fetal outcomes were followed up. Data were analyzed using Kaplan–Meier and logistic regression analyses. In mild PE patients, thrombin time (p = .000), platelet distribution width (PDW) (p = .000), and clot formation time (p = .000) were increased, while prothrombin time (p = .000) and fibrinogen (p = .045) were reduced. With increasing PE severity, prothrombin time (p = .000), platelet count (PLT) (p = .000), mean platelet volume (MPV) (p = .000), plateletcrit (p = .000), maximum amplitude (MA) (p = .000), and coagulation index (p = .001) decreased, whereas activated partial thromboplastin time (APTT) (p = .000), thrombin time (p = .002), D-dimer (p = .026), and PDW (p = .000) increased. Lower prothrombin time (p = .048), PLT (p = .004), and coagulation index (p = .026) or higher APTT (p = .032), thrombin time (p = .044), D-dimer (p = .023), and PDW (p = .016) were associated with a higher risk of poor pregnancy outcomes. Thrombin time was identified as an independent risk factor (p = .025, OR = 2.918, 95% CI: 1.145–7.436), whereas gestational age was an independent protective factor (p = .000, OR = 0.244, 95% CI: 0.151–0.395). This study demonstrates that specific coagulation and platelet parameters are significantly associated with PE severity and adverse pregnancy outcomes. These findings highlight the importance of monitoring coagulation function in PE patients to improve clinical management and outcomes.
{"title":"Changes of coagulation function and platelet parameters in preeclampsia and their correlation with pregnancy outcomes","authors":"Juan Peng MM, Quxi Zhao MM, Wei Pang MM, Yanjuan Li MM, Xudong Dong PhD","doi":"10.1111/jch.14893","DOIUrl":"10.1111/jch.14893","url":null,"abstract":"<p>Preeclampsia (PE) is a severe pregnancy complication characterized by significant alterations in coagulation function. This study aims to analyze the correlation between coagulation function, platelet parameters, and pregnancy outcomes in PE patients. Clinical data, along with blood and urine samples, were collected from 168 PE patients and 128 healthy pregnant women. General demographic and laboratory testing data were recorded, and maternal and fetal outcomes were followed up. Data were analyzed using Kaplan–Meier and logistic regression analyses. In mild PE patients, thrombin time (<i>p</i> = .000), platelet distribution width (PDW) (<i>p</i> = .000), and clot formation time (<i>p</i> = .000) were increased, while prothrombin time (<i>p</i> = .000) and fibrinogen (<i>p</i> = .045) were reduced. With increasing PE severity, prothrombin time (<i>p</i> = .000), platelet count (PLT) (<i>p</i> = .000), mean platelet volume (MPV) (<i>p</i> = .000), plateletcrit (<i>p</i> = .000), maximum amplitude (MA) (<i>p</i> = .000), and coagulation index (<i>p</i> = .001) decreased, whereas activated partial thromboplastin time (APTT) (<i>p</i> = .000), thrombin time (<i>p</i> = .002), D-dimer (<i>p</i> = .026), and PDW (<i>p</i> = .000) increased. Lower prothrombin time (<i>p</i> = .048), PLT (<i>p</i> = .004), and coagulation index (<i>p</i> = .026) or higher APTT (<i>p</i> = .032), thrombin time (<i>p</i> = .044), D-dimer (<i>p</i> = .023), and PDW (<i>p</i> = .016) were associated with a higher risk of poor pregnancy outcomes. Thrombin time was identified as an independent risk factor (<i>p</i> = .025, OR = 2.918, 95% CI: 1.145–7.436), whereas gestational age was an independent protective factor (<i>p</i> = .000, OR = 0.244, 95% CI: 0.151–0.395). This study demonstrates that specific coagulation and platelet parameters are significantly associated with PE severity and adverse pregnancy outcomes. These findings highlight the importance of monitoring coagulation function in PE patients to improve clinical management and outcomes.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 10","pages":"1181-1187"},"PeriodicalIF":2.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chiranjeevee R. Saravanan MBBS, Shubhayu R. Chowdhury MBBS, Pugazhendi Inban MD, Sai Harini Chandrasekaran MBBS, Himani H. Pattani MBBS, Krupanagram Santoshi MBBS, Hyma Bamba MBBS, Gurmehar Singh MBBS, Priyadarshi Prajjwal MBBS, Raunak Ranjan MD, Mohammed Dheyaa Marsool Marsool MBChB, Omniat Amir MBBS
Cardio-ankle vascular index (CAVI) is an innovative indicator of large-artery stiffness, which is evaluated by the pulse wave velocity (PWV) measurement. Mortality and morbidity due to cardiovascular diseases among the general public with high-risk conditions such as hypertension are usually associated with arterial stiffness. CAVI modelizes the hazard of future cardiovascular events with standard risk factors. Additionally, the “European Society of Hypertension and Cardiology” included the aortic PWV assessment in managing hypertension in their updated guidelines in 2007. We conducted this systematic review to collect, summarize, and evaluate the evidence from relevant reported studies. A literature search of four databases was conducted comprehensively until February 2024. Cardiovascular events are the primary outcome of interest in this study, cardiovascular events that have been defined as major adverse cardiac events include “heart failure”, “stroke”, “myocardial infarction”, “cardiovascular deaths”, “stable angina pectoris”, “coronary revascularization”, and “unstable angina pectoris”. We included five studies with a 11 698 sample size in this systematic review. All five prospective studies investigated composite cardiovascular events as an outcome. Three of them revealed a statistically significant prediction ability of CAVI to assess Cardiovascular disease (CVD) risk. Further analysis is required. Current evidence is insufficient to confirm the predictive power of CAVI in the assessment of cardiovascular risk in hypertensive patients. CAVI is modestly associated with incidents of CVD risk. It is necessary to conduct further studies to assess CAVI concerning CVD predictor measures in the masses and nations other than Asia.
{"title":"Predictive significance of cardio ankle vascular index for the assessment of cardiovascular risk in hypertensive patients: A systematic review","authors":"Chiranjeevee R. Saravanan MBBS, Shubhayu R. Chowdhury MBBS, Pugazhendi Inban MD, Sai Harini Chandrasekaran MBBS, Himani H. Pattani MBBS, Krupanagram Santoshi MBBS, Hyma Bamba MBBS, Gurmehar Singh MBBS, Priyadarshi Prajjwal MBBS, Raunak Ranjan MD, Mohammed Dheyaa Marsool Marsool MBChB, Omniat Amir MBBS","doi":"10.1111/jch.14878","DOIUrl":"10.1111/jch.14878","url":null,"abstract":"<p>Cardio-ankle vascular index (CAVI) is an innovative indicator of large-artery stiffness, which is evaluated by the pulse wave velocity (PWV) measurement. Mortality and morbidity due to cardiovascular diseases among the general public with high-risk conditions such as hypertension are usually associated with arterial stiffness. CAVI modelizes the hazard of future cardiovascular events with standard risk factors. Additionally, the “European Society of Hypertension and Cardiology” included the aortic PWV assessment in managing hypertension in their updated guidelines in 2007. We conducted this systematic review to collect, summarize, and evaluate the evidence from relevant reported studies. A literature search of four databases was conducted comprehensively until February 2024. Cardiovascular events are the primary outcome of interest in this study, cardiovascular events that have been defined as major adverse cardiac events include “heart failure”, “stroke”, “myocardial infarction”, “cardiovascular deaths”, “stable angina pectoris”, “coronary revascularization”, and “unstable angina pectoris”. We included five studies with a 11 698 sample size in this systematic review. All five prospective studies investigated composite cardiovascular events as an outcome. Three of them revealed a statistically significant prediction ability of CAVI to assess Cardiovascular disease (CVD) risk. Further analysis is required. Current evidence is insufficient to confirm the predictive power of CAVI in the assessment of cardiovascular risk in hypertensive patients. CAVI is modestly associated with incidents of CVD risk. It is necessary to conduct further studies to assess CAVI concerning CVD predictor measures in the masses and nations other than Asia.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 9","pages":"1005-1014"},"PeriodicalIF":2.7,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.14878","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhilan Ma MM, Yan Wang MM, Xiaoyan Guo MM, Lan Ma MM, Yonghua Liu MM, Xiaoling Zhou MM
This was a retrospective study. This study investigated the occurrence of a composite endpoints (cardiovascular and cerebrovascular events, end-stage renal disease, and death) in 153 patients (aged ≥ 18 years) with a diagnosis of in chronic kidney disease (CKD). Based on morning blood pressure surge (MBPS) defined as ≥35 mm Hg, patients were divided into two groups: with MBPS (n = 50) and without MBPS (n = 103). All patients were followed up for at least 1 year. Baseline demographic, laboratory and follow-up data were collected. The clinical characteristics of the two groups were compared. The relationships between MBPS and endpoint events were analyzed using the Kaplan–Meier method and Cox regression model. In total, 153 patients (mean age 41.8 years; 56.86% males) were included in this study. During the follow-up period (mean 4.3 years), 34 endpoint events occurred. After adjustment for the covariates, the risk of cardiovascular and cerebrovascular events, end-stage renal disease and death remained significantly higher in patients with MBPS (hazard ratio [HR] and 95% confidence interval [CI] 3.124 [1.096–9.130]]) Among the other variables, systolic blood pressure, and night-time and daytime pulse pressures remained significantly associated with outcome in patients of CKD (1.789 [1.205–2.654], 1.710 [1.200–2.437], and 1.318 [1.096–1.586], respectively]. In conclusions, MBPS was identified as an independent prognostic factor for composite endpoint events (cardiovascular and cerebrovascular events, end-stage renal disease and death) patients with chronic kidney disease patients.
{"title":"Prognostic value of morning blood pressure surge in chronic kidney disease","authors":"Zhilan Ma MM, Yan Wang MM, Xiaoyan Guo MM, Lan Ma MM, Yonghua Liu MM, Xiaoling Zhou MM","doi":"10.1111/jch.14885","DOIUrl":"10.1111/jch.14885","url":null,"abstract":"<p>This was a retrospective study. This study investigated the occurrence of a composite endpoints (cardiovascular and cerebrovascular events, end-stage renal disease, and death) in 153 patients (aged ≥ 18 years) with a diagnosis of in chronic kidney disease (CKD). Based on morning blood pressure surge (MBPS) defined as ≥35 mm Hg, patients were divided into two groups: with MBPS (<i>n</i> = 50) and without MBPS (<i>n</i> = 103). All patients were followed up for at least 1 year. Baseline demographic, laboratory and follow-up data were collected. The clinical characteristics of the two groups were compared. The relationships between MBPS and endpoint events were analyzed using the Kaplan–Meier method and Cox regression model. In total, 153 patients (mean age 41.8 years; 56.86% males) were included in this study. During the follow-up period (mean 4.3 years), 34 endpoint events occurred. After adjustment for the covariates, the risk of cardiovascular and cerebrovascular events, end-stage renal disease and death remained significantly higher in patients with MBPS (hazard ratio [HR] and 95% confidence interval [CI] 3.124 [1.096–9.130]]) Among the other variables, systolic blood pressure, and night-time and daytime pulse pressures remained significantly associated with outcome in patients of CKD (1.789 [1.205–2.654], 1.710 [1.200–2.437], and 1.318 [1.096–1.586], respectively]. In conclusions, MBPS was identified as an independent prognostic factor for composite endpoint events (cardiovascular and cerebrovascular events, end-stage renal disease and death) patients with chronic kidney disease patients.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 10","pages":"1155-1162"},"PeriodicalIF":2.7,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142005766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}